Author Interview: Dr. Eva Mistry on “Predicting 90-Day Outcome After Thrombectomy: Baseline-Adjusted 24-Hour NIHSS Is More Powerful Than NIHSS Score Change”
A conversation with Dr. Eva Mistry, MBBS, MSCI, Assistant Professor of Clinical Neurology and Rehabilitation, University of Cincinnati, on predicting 90-day outcome following thrombectomy.
Interviewed by Dr. Yasmin N. Aziz, MD, T32 Stroke Fellow, University of Cincinnati.
They will be discussing the paper “Predicting 90-Day Outcome After Thrombectomy: Baseline-Adjusted 24-Hour NIHSS Is More Powerful Than NIHSS Score Change,” published in the August 2021 issue of Stroke.
Dr. Aziz: How did the idea behind this paper come to fruition?
Dr. Mistry: To help emphasize the importance of choosing ideal surrogate markers and their correct definitions. When we are developing tools to identify most efficacious acute stroke therapies that improve patient outcomes, and the surrogate outcome measures that we use to predict these patient-centered outcomes are flawed, then all that follows will be flawed as well. Ultimately, there is a real need for solid surrogate markers in acute stroke studies. NIHSS-based surrogate outcome measures are widely used in acute stoke trials. However, they are defined heterogeneously. With the paper, we wanted to establish the pros and cons of using various definitions NIHSS-based surrogate markers, and especially to show how each of them predict the patient-centered outcomes of 90-day modified Rankin Scores.